Notably, GSK3β agonists wortmannin have been found to limit the positive effects of AMPK on AD, emphasizing the pivotal role of GSK3β in AMPK‐mediated suppression of p‐tau.139. This evidence concerns the gene MAPT and Alzheimer disease.